Nav: Home

NAD can restore mitochondrial function and energy production in MTDPS liver-like cells

November 06, 2018

Mitochondria are responsible for supplying the cell with energy in the form of ATP through oxidative phosphorylation. There is a group of rare, autosomal recessive disorders, known as Mitochondrial DNA Depletion Syndromes (MTDPS), which causes a significant reduction in mitochondrial DNA (mtDNA) and ATP production. There is no treatment for MTDPS, and it is typically fatal during infancy as a result of liver failure. Researchers at the Medical University of South Carolina (MUSC) have identified several drug candidates for the treatment of MTDPS. Their results, published online in the November 6, 2018 issue of Cell Reports, showed that nicotinamide adenine dinucleotide (NAD) significantly restored mitochondrial function in vitro as well as in preclinical animal models.

MTDPS has recently received international attention after an infant, Charlie Gard, became the subject of a 'best interests' case in the UK, drawing criticism from world leaders including Pope Francis and President Trump. Doctors determined that Gard had a mutation in ribonucleoside-diphosphate reductase subunit M2 B (RRM2B), a protein critical for generating the building blocks of mtDNA and one of several causes of MTDPS. Unfortunately, with no cure or treatment available, Gard passed away in July 2017, after battling MTDPS for 11 months, 24 days.

"We realized that there really is no treatment for these diseases. So we thought that we could start to use our stem cell model systems to try and find drugs or therapeutics" says Stephen A. Duncan, D. Phil., SmartState™ Chair of Regenerative Medicine at MUSC and senior author on this study.

The discovery of new treatments has been hampered by the lack of a model that fully mimics the pathology of MTDPS. Furthermore, primary liver cells from patients are difficult to obtain and to work with. To solve this problem, Duncan and his team used CRISPR/Cas9 to deplete deoxyguanosine kinase (DGUOK) in human induced pluripotent stem cells. Then, using protocols established in the Duncan laboratory, they differentiated those knock-out cells into liver-like cells.

The most common MTDPS, representing 15 - 30 percent of cases, results from the loss of DGUOK. In patients, the loss of DGUOK reduces the pools of precursor molecules needed to synthesize mtDNA, resulting in low mtDNA levels and diminished ATP levels. The DGUOK-deficient cells similarly exhibited a reduction in mtDNA levels, loss of ATP production and a disorganized mitochondrial morphology. These phenotypes could be reversed by the addition of precursors for mtDNA synthesis as well as re-expression of DGUOK.

"Having recapitulated this disease, the next question was can we find drugs that can reverse it," says Duncan.

The next stage of this study utilized a library of drugs that are currently available on the market, to perform a phenotypic screen for drugs that could restore ATP levels. The screen identified 15 drugs, impacting a variety of metabolic processes, which significantly increased ATP levels. Unexpectedly, the drug with the greatest impact on ATP production was nicotinamide adenine dinucleotide (NAD), a coenzyme that impacts several pathways. The researchers went on to show that NAD functions through the activation of a transcription cascade that results in increased expression of mitochondrial proteins involved in ATP production.

"Because the iPSC-derived hepatocytes enabled us to perform an unbiased, phenotypic screen, we were able to identify unanticipated drugs like NAD," says Ran Jing, Ph.D., first author and graduate student in the Duncan lab, who is now a postdoctoral fellow at Harvard Medical School.

To complete their studies, the researchers validated their findings using DGUOK-deficient rats. These animals do not succumb to disease; however their livers are still affected and show diminished ATP production. In animal models, NAD exhibits poor bioavailability, so researchers utilized the NAD precursor nicotinamide riboside (NR). Treating DGUOK-deficient rats that exhibit disease symptoms with NR partially restored their ATP levels when compared to wild-type rats. This finding has significant implications for clinically treating MTDPS patients.

"It's not that you need to treat during development, you should be able to treat patients after the phenotype has developed and reverse it, rather than just preventing it," explains Duncan.

To broaden the scope of these findings to other forms of MTDPS, the Duncan lab also generated RRM2B-deficient liver-like cells, the same mutation that lead to MTDPS in Charlie Gard. These cells exhibited reduced mtDNA and ATP levels, albeit not as drastically as DGUOK-deficient cells. Despite this, addition of NAD restored ATP levels in RRM2B-deficient cells, showing that NAD may provide a treatment for multiple forms of MTDPS.

The powerful phenotypic screen conducted in this study identified multiple drugs that increased ATP production. To further restore mitochondrial function, the researchers treated DGUOK-deficient cells with a combination of NAD and trimipramine, a drug used to treat depression, and found that ATP levels were further increased, exceeding levels observed in WT cells. Follow-up studies using other drug combinations may further refine the best course of treatment for MTDPS.

Overall, this research highlights how basic science research supports translational and clinical medicine.

"What starts out as a curiosity ends up rapidly opening up potential treatments for kids that are really sick or dying," says Duncan.
-end-
About MUSC

Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry. For more information on academic information or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.

EMBARGOED UNTIL 11am (ET US) on November 6, 2018

Medical University of South Carolina

Related Mitochondrial Dna Articles:

Mitochondrial disease has a disproportionate healthcare burden in US
Mitochondrial diseases are a diverse group of disorders caused by mutated genes that impair energy production in a patient's cells, often with severe effects.
The art of folding mitochondrial membranes
Oliver Daumke's lab figures out how the inner membranes of mitochondria 'get their groove' and assume the complex shapes they need to carry out crucial cellular functions.
New online database has answers on mitochondrial disorders
Providing answers - or at least more information - to the most difficult medical questions is the aim of medical scientists.
How to protect cells from selfish mitochondrial DNA
Using yeast cells as a model, scientists from the A.N.
Nuclear transfer of mitochondrial DNA in colon and rectal cancer
Patients with colon and rectal cancer have somatic insertions of mitochondrial DNA into the nuclear genomes of the cancer cells, UAB researchers report in the journal Genome Medicine.
FASEB Science Research Conference: Mitochondrial Biogenesis
The central role of mitochondria in normal cell physiology is evident from human diseases, including metabolic disorders and aging, which are associated with changes in mitochondrial function.
Mitochondrial DNA shows past climate change effects on gulls
To understand the present and future, we have to start with the past.
New research provides key insight about mitochondrial replacement therapy
A new study suggests a method for conducting mitochondrial replacement therapy in such a way that safely prevents the transmission of harmful mitochondrial gene mutations from mothers to their children.
Study shows link between mitochondrial DNA and autism
Cornell University researchers have confirmed a genetic link between mitochondrial DNA (mtDNA), which is passed on from the mother, and some forms of autism spectrum disorder (ASD).
Autism spectrum disorder linked to mutations in some mitochondrial DNA
Children diagnosed with autism spectrum disorder have greater numbers of harmful mutations in their mitochondrial DNA than family members, report Zhenglong Gu of Cornell University in Ithaca, New York, and colleagues, in a study published Oct.

Related Mitochondrial Dna Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...